The Japanese Journal of Antibiotics
Online ISSN : 2186-5477
Print ISSN : 0368-2781
ISSN-L : 0368-2781
Volume 73, Issue 2
Displaying 1-3 of 3 articles from this issue
Case Report
Research Report
  • Satomi Takei, Ayako Nakamura, Toshihiro Takahashi, Takaaki Kawakami, M ...
    2020 Volume 73 Issue 2 Pages 45-53
    Published: June 25, 2020
    Released on J-STAGE: June 20, 2024

    The MASTDISCS combi Carba plus is a set of inhibitor combination discs that differentiates carbapenemases from AmpC β-lactamases. We evaluated the performance of this disc set in discriminating β-lactamase genotypes using 36 clinical and 5 reference strains, as well as discriminating clinical isolates using phenotypic assays. The results for all Enterobacteriaceae strains producing 21 carbapenemases (16 clinical isolates and 5 reference strains), including 14 IMP-1, 1 VIM-1, 2 NDM, 2 OXA-48, and 2 KPC carbapenemases, using the MASTDISCS combi Carba plus were consistent with the genotypes identified by multiplex PCR. Sixteen carbapenemase-producing Enterobacteriaceae clinical isolates were positive for carbapenemase production according to the modified carbapenem inactivation methodology, and 13 MBL-producing strains were positive for carbapenemase production according to the sodium mercaptoacetic acid double disc synergy test. Twenty-one of the AmpC β-lactamase- and ESBL-producing strains were identified as AmpC- or non-carbapenemase-producing Enterobacteriaceae using the MASTDISCS combi Carba plus. Ten AmpC β-lactamase-producing clinical strains were all positive for the aminophenyl boronic acid double disc synergy test. Overall, the MASTDISCS combi Carba plus allowed easy identification and successful typing of major carbapenemases using routine microbiology methods.

    Download PDF (1221K)
  • Yuki Asai, Takanori Yamamoto, Naohiro Suzuyama, Arisa Matsuda, Fumitak ...
    2020 Volume 73 Issue 2 Pages 55-63
    Published: June 25, 2020
    Released on J-STAGE: June 20, 2024

    The dosage of many antimicrobial agents must be adjusted for renal function. However, pharmacists could not perform proper inquiries into the dose adjustment of antimicrobial agents by doctors owing to variations in the knowledge and experience of pharmacists. In this study, two systems were constructed to check the dosage of the prescriptions according to the patient’s renal function. First, [kidney] was displayed on the order screen above the name of any oral antimicrobial drug that is eliminated mainly by the kidney. Second, the dosage reduction rate was shown on the prescription, and the parameters of renal function were indicated in the remarks column. In the 6 months before and after deployment of these systems, the rate of questions of the prescription was 1.01%(14/1380)and 1.56%(20/1280), respectively. Before these systems were implemented, only the dosage of levofloxacin was inquired about; after implementation, the dosage of three antimicrobial drugs was inquired about, suggesting that these systems may be useful to allow pharmacists to determine the appropriate dose. Moreover, doctors could use these systems for voluntary dose adjustment based on renal function. This study clarified that the checking systems for dosage antimicrobial agents based on renal function may contribute to the proper use of oral antimicrobial agents.

    Download PDF (1109K)